Literature DB >> 17134640

Identifying patients for aggressive cholesterol lowering: the risk curve concept.

Jennifer G Robinson, Neil J Stone.   

Abstract

The National Cholesterol Education Program's 2004 report identified more aggressive optional low-density lipoprotein (LDL) cholesterol treatment goals of <70 mg/dl for secondary prevention patients and <100 mg/dl for moderately high risk, primary prevention patients. Although LDL cholesterol reduction is the first step in reducing cardiovascular risk, it may be difficult for clinicians to visualize the risk reduction benefit for patients from various risk interventions. The concept of a "risk curve," or the absolute risk of a patient for subsequent cardiovascular events over a range of LDL cholesterol values, is proposed. In conclusion, placing a patient on the appropriate risk curve may facilitate an individualized clinical management strategy that takes into account the patient's absolute benefit from further LDL cholesterol reduction as well as from shifting the risk curve downward through non-LDL cholesterol interventions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17134640     DOI: 10.1016/j.amjcard.2006.06.039

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men.

Authors:  Jennifer G Robinson; Catherine Rahilly-Tierney; Elizabeth Lawler; J Michael Gaziano
Journal:  J Clin Lipidol       Date:  2011-11-07       Impact factor: 4.766

Review 2.  LDL reduction: how low should we go and is it safe?

Authors:  Jennifer G Robinson
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

Review 3.  Is a statin as part of a polypill the answer?

Authors:  Jennifer G Robinson
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

Review 4.  Atorvastatin: pharmacological characteristics and lipid-lowering effects.

Authors:  Andrea Poli
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Statin Prescribing in the Elderly: Special Considerations.

Authors:  M Leya; N J Stone
Journal:  Curr Atheroscler Rep       Date:  2017-10-11       Impact factor: 5.113

6.  Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol.

Authors:  Soo Youn Lee; Seung-Jin Oh; Eung Ju Kim; Chi-Yoon Oum; Sung Hwan Park; Jaewon Oh; Jung-Sun Kim; Byeong-Keuk Kim; Sungha Park; Hyuk-Jae Chang; Geu-Ru Hong; Young-Guk Ko; Seok-Min Kang; Donghoon Choi; Jong-Won Ha; Myeong-Ki Hong; Yangsoo Jang; Namsik Chung; Sang-Hak Lee
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

7.  Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting.

Authors:  Rutger Verbeek; Renate M Hoogeveen; Anne Langsted; Lotte C A Stiekema; Simone L Verweij; G Kees Hovingh; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Børge G Nordestgaard; Erik S G Stroes
Journal:  Eur Heart J       Date:  2018-07-14       Impact factor: 29.983

Review 8.  Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.

Authors:  Jennifer G Robinson
Journal:  Vasc Health Risk Manag       Date:  2009-04-08

9.  Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl.

Authors:  Jennifer G Robinson; Manju Bengaluru Jayanna; C Noel Bairey Merz; Neil J Stone
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.